Shandong Keyuan Pharmaceutical Co (SZSE:301281) Total Assets: ¥1,790.8 Mil (As of Mar. 2026)


SZSE:301281 Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
67 GF Score
Price ¥46.62
GF Value ¥30.42
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Shandong Keyuan Pharmaceutical Co Total Assets?

Shandong Keyuan Pharmaceutical Co SZSE:301281 -7.54% 67 Total Assets is ¥1,790.8 Mil as of Mar. 2026. GuruFocus rates SZSE:301281 with a GF Score™ of 67/100 and a GF Value™ of ¥30.42 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Shandong Keyuan Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2026 was ¥1,790.8 Mil.

During the past 12 months, Shandong Keyuan Pharmaceutical Co's average Total Assets Growth Rate was 21.10% per year. During the past 3 years, the average Total Assets Growth Rate was 38.20% per year. During the past 5 years, the average Total Assets Growth Rate was 28.90% per year. During the past 10 years, the average Total Assets Growth Rate was 23.80% per year.

During the past 13 years, Shandong Keyuan Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 53.80%. The lowest was -2.70%. And the median was 23.50%.

Total Assets is connected with ROA %. Shandong Keyuan Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2026 was 6.92%. Total Assets is also linked to Revenue through Asset Turnover. Shandong Keyuan Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2026 was 0.09.


Shandong Keyuan Pharmaceutical Co  (SZSE:301281) Total Assets Explanation

Total Assets is connected with ROA %.

Shandong Keyuan Pharmaceutical Co's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=120.292/( (1687.665+1790.796)/ 2 )
=120.292/1739.2305
=6.92 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shandong Keyuan Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=161.303/( (1687.665+1790.796)/ 2 )
=161.303/1739.2305
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shandong Keyuan Pharmaceutical Co Total Assets Related Terms


Shandong Keyuan Pharmaceutical Co Total Assets Historical Data

* Premium members only.

The historical data trend for Shandong Keyuan Pharmaceutical Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Keyuan Pharmaceutical Co Total Assets Chart

Shandong Keyuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 559.51 651.79 1,469.97 1,552.47 1,687.67

Shandong Keyuan Pharmaceutical Co Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,576.01 1,604.35 1,605.85 1,687.67 1,790.80
SZSE:301281
67GF Score
Shandong Keyuan Pharmaceutical Co Ltd SZSE:301281
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Keyuan Pharmaceutical Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shandong Keyuan Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1356.182+331.483
=1,687.7

Shandong Keyuan Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1393.395+397.401
=1,790.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of ¥1,790.8 Mil mean?
Shandong Keyuan Pharmaceutical Co (SZSE:301281) has a Total Assets of ¥1,790.8 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors.
Is Shandong Keyuan Pharmaceutical Co's Total Assets too high?
Shandong Keyuan Pharmaceutical Co's current Total Assets is ¥1,790.8 Mil. Overall, Shandong Keyuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shandong Keyuan Pharmaceutical Co's Total Assets compare to LLY and JNJ?
Shandong Keyuan Pharmaceutical Co's Total Assets of ¥1,790.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Shandong Keyuan Pharmaceutical Co and its competitors. Shandong Keyuan Pharmaceutical Co's current Total Assets is ¥1,790.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Keyuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co (SZSE:301281) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥30.42, compared to a current price of ¥46.62 — trading 53.3% above its estimated fair value. The current Total Assets is ¥1,790.8 Mil. Shandong Keyuan Pharmaceutical Co's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Shandong Keyuan Pharmaceutical Co (SZSE:301281), the current Total Assets is ¥1,790.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Keyuan Pharmaceutical Co (SZSE:301281) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Keyuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥46.62 is trading 53.3% above its estimated GF Value™ of ¥30.42. GuruFocus considers Shandong Keyuan Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SZSE:301281:

  • Total Assets: ¥1,790.8 Mil
  • GF Value™: ¥30.42 vs. price of ¥46.62 (53.3% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the SZSE:301281 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Keyuan Pharmaceutical Co Business Description

Address Keyuan Street, Shandong Shanghe Economic Development Zone, Shandong Province, Jinan, CHN, 251601
Shandong Keyuan Pharmaceutical Co Ltd is engaged in the research and development, production, and sales of chemical raw materials and their preparations.
67GF Score

Get the complete analysis for SZSE:301281

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥46.62
Price
¥30.42
GF Value